Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)

<p>November 10, 2022 - New York, NY &ndash; Cellectis (the &ldquo;Company&rdquo;) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published a manuscript in Frontiers Bioengineering and Biotechnology demonstrating the feasibility of efficient multiplex gene engineering using a combination of two different molecular tools: Cellectis&rsquo; TALEN&reg; gene editing technology (TALE nuclease) and a TALE-BE (TALE Base editor).</p>

<p>TALE base editors are a recent and very important addition to the gene editing landscape. This approach does not create DNA double strand breaks as does CRISPR/Cas9, or other engineered nucleases, and is a promising therapeutic strategy for genetic diseases. A key aspect to broaden the scope of possible applications is our comprehension of design rules.</p>

<p>Cellectis used a screening approach to gain in-depth insights into the editing rules driving TALE-BE activity and applied this knowledge to design highly efficient TALE-BE compatible with potential therapeutic application. Moreover, TALE-BE show insignificant levels of by-products such as indels.</p>

<p>Cellectis scientists combined two molecular tools, a TALEN&reg; and a TALE-BE, to perform a double gene Knock Out (KO) of TRAC and CD52, a combination of target genes used for allogeneic CAR T-cell adoptive therapies. This combination of molecular tools paves the way to simultaneous multiplex gene engineering with more controllable outcomes.</p>

<p>&ldquo;A multiplex/multitool strategy presents several advantages: firstly, it prevents the creation of translocations often observed with the simultaneous use of several nucleases. Secondly, it allows for the possibility of going beyond multiple knock-outs while still allowing gene knock-in at the nuclease target site, altogether extending the scope of possible application,&rdquo; said Alex Juillerat, Ph.D., Vice President Gene Editing &amp; New York Lab Head at Cellectis. &ldquo;The precise positional rules we have determined for TALE-BE will allow Cellectis to unleash the full potential of these technologies for future applications.&rdquo;</p>

<p>Research data showed that:</p>

<p>&middot; Employing a medium/high throughput strategy, Cellectis gained in-depth insight of the editing rules in cellulo, while excluding confounding factors.</p>

<p>&middot; Designed TALE-BE targeting CD52 achieved very high frequency of gene knock-out (up to 80% of phenotypic CD52 knock out).</p>

<p>&middot; When TALE-BE was combined with a TALEN&reg; targeting the TRAC locus, very high frequency of double gene knock-out (up to 75% of phenotypic double gene knock-out) was achieved without the creation of translocations between the two targeted loci.</p>

<p>This article is available on Frontiers in Bioengineering and Biotechnology website by clicking on <a href="https://www.frontiersin.org/articles/10.3389/fbioe.2022.1033669/abstract">this link.</a></p>